Cerity Partners
NTLA icon

Cerity Partners’s Intellia Therapeutics NTLA Stock Holding History

Cerity Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$323K Sell
19,062
-3,470
-15% -$48.6K ﹤0.01% 2741
2026
Q1 		$289K Buy
+22,532
New +$287K ﹤0.01% 2636

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Cerity Partners's NTLA Position: Q2 2026 in Review

Cerity Partners reduced its Intellia Therapeutics (NTLA) stake by 15% in Q2 2026, selling an estimated $48.6K and leaving 19,062 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #2741.

Cerity Partners first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Cerity Partners held 19,062 shares of Intellia Therapeutics worth $323K as of Q2 2026.
  • Cerity Partners sold 3,470 Intellia Therapeutics shares in Q2 2026, an estimated $48.6K.
  • Intellia Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2741 holding.
  • Cerity Partners first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.